Business Context and Reporting Period
This Form 6-K filing by OKYO Pharma Ltd covers the reporting period of March 19, 2026. The filing serves to disclose a specific corporate event regarding share acquisition by an entity affiliated with the company's Executive Chairman.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of a transaction rather than a financial performance statement.
Material Changes
The primary material change disclosed is the acquisition of 10,119 ordinary shares of OKYO Pharma Ltd by Panetta Partners Limited. This entity holds a beneficial interest for Gabriele Cerrone, the Executive Chairman. The transaction occurred on the NASDAQ at a price of $1.59 per share, increasing Cerrone's total holding to 10,526,416 shares.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The document explicitly states that the attached news announcement (Exhibit 99.1) is furnished and not deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934.
Investor Verification Checklist
- Verify the total beneficial ownership percentage of Gabriele Cerrone following this acquisition.
- Confirm the current trading price of OKYO Pharma Ltd shares on NASDAQ relative to the $1.59 transaction price.
- Review the full text of Exhibit 99.1 for any additional context regarding the acquisition strategy.
- Check for any subsequent filings regarding further insider trading activity.